-
Company Insights
Innovation and Patenting activity of SMA Solar Technology AG Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of SMA Solar Technology AG Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vartocell in Spinal Muscular Atrophy (SMA)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vartocell in Spinal Muscular Atrophy (SMA) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Vartocell in Spinal Muscular Atrophy (SMA)Drug Details:Vartocell is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Talditercept Alfa in Spinal Muscular Atrophy (SMA)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Talditercept Alfa in Spinal Muscular Atrophy (SMA) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talditercept Alfa in Spinal Muscular Atrophy (SMA) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6237 in Spinal Muscular Atrophy (SMA)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RG-6237 in Spinal Muscular Atrophy (SMA) Drug Details: RG-6237 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NMDP-02 in Spinal Muscular Atrophy (SMA)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NMDP-02 in Spinal Muscular Atrophy (SMA) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NMDP-02 in Spinal Muscular Atrophy (SMA) Drug Details: NMDP-02 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BIIB-115 in Spinal Muscular Atrophy (SMA)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BIIB-115 in Spinal Muscular Atrophy (SMA) Drug Details: BIIB-115 is under development for the treatment of...
-
Product Insights
NewHyaluronic Acid Fillers Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Hyaluronic Acid Fillers Pipeline Market Report Overview Hyaluronic Acid (HA) is a glycosaminoglycan disaccharide, which exists naturally in the body. Approximately 50% of the total HA is found in the skin. Injections of HA are used for reducing wrinkles in the face and for soft tissue augmentation. The hyaluronic acid fillers pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Camrelizumab in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Camrelizumab in Cervical Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Camrelizumab in Cervical Cancer Drug Details: Camrelizumab (Airuika) is a humanized monoclonal...
-
Product Insights
NewAesthetic Injectables Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Aesthetic Injectables Pipeline Market Report Overview Aesthetic injectables are gel-like substances injected beneath the skin to restore a youthful appearance by increasing the volume of sunken cheeks or temples or reducing lines around the nose and mouth, among other processes. Aesthetic Injectables are grouped into segments based on their molecular composition. The aesthetic injectables pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6237 in Facioscapulohumeral Muscular Dystrophy (FSHD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RG-6237 in Facioscapulohumeral Muscular Dystrophy (FSHD) Drug Details: RG-6237 is under development for the treatment...